Article Text

Download PDFPDF
Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with giant cell arteritis? Comment on the paper of Espigol-Frigole et al
  1. Maxime Samson1,2,3,
  2. Sylvain Audia1,2,3,
  3. Nona Janikashvili2,3,
  4. Bernard Bonnotte1,2,3
  1. 1Service de Medecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire de Dijon, Dijon, France
  2. 2INSERM, UMR1098, Besancon Cedex, France
  3. 3Faculte de Medecine, Universite de Bourgogne, IFR100, Dijon, France
  1. Correspondence to Dr Maxime Samson, Service de Medecine Interne et Immunologie Clinique, CHU de Dijon, 2 Bd Mal de Lattre de Tassigny, 21000 Dijon, France; Faculty of Medicine, INSERM UMR1098, University of Burgundy, 21000 Dijon, France; samsonmaxime{at}

Statistics from

We have read with interest the recently published paper of Espigol-Frigole et al1 in which the authors confirmed that interleukin (IL)-17 is highly expressed in giant cell arteritis (GCA) lesions.1–3 They also demonstrated for the first time that IL-17 expression in temporal artery biopsies (TABs) was correlated with a better outcome. Among other interesting results, the identification of Foxp3+IL-17+ T cells by confocal microscopy in TAB made the authors to hypothesize that these cells could be induced regulatory T cells (Treg) that may facilitate the remission of the disease under steroid therapy. …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.